How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?
- 20 June 2000
- Vol. 27 (1) , 1-3
- https://doi.org/10.1016/s8756-3282(00)00301-x
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Early Changes in Biochemical Markers of Bone Turnover Predict the Long-Term Response to Alendronate Therapy in Representative Elderly Women: A Randomized Clinical TrialJournal of Bone and Mineral Research, 1998
- Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.Journal of Clinical Investigation, 1997
- Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective studyJournal of Bone and Mineral Research, 1996
- Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fracturesBMJ, 1996
- Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatmentJournal of Clinical Endocrinology & Metabolism, 1994
- Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosisThe American Journal of Medicine, 1993
- Pre-Existing Fractures and Bone Mass Predict Vertebral Fracture Incidence in WomenAnnals of Internal Medicine, 1991
- Effect of Fluoride Treatment on the Fracture Rate in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 1990
- Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment.Journal of Clinical Investigation, 1988
- Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss.Journal of Clinical Investigation, 1983